• 1. Excitable dynamics in the bromate–sulfite–ferrocyanide reaction
  J. Zagora,M. Vosla?,L. Schreiberová,I. Schreiber Phys. Chem. Chem. Phys., 2002,4, 1284-1291
• 2. Establishing the accuracy of position-specific carbon isotope analysis of propane by GC-pyrolysis-GC-IRMS
  ChangjieLiu,PengLiu,XiaofengWang,XiaoqiangLi,JuskeHorita
• 3. Evolution of calcium phosphate precipitation in hanging drop vapor diffusion by in situRaman microspectroscopy
  Gloria Belén Ramírez-Rodríguez,José Manuel Delgado-López,Jaime Gómez-Morales CrystEngComm, 2013,15, 2206-2212
• 4. Empowering microfluidics by micro-3D printing and solution-based mineral coating?
  Hongxia Li,Aikifa Raza,Qiaoyu Ge,Jin-You Lu,TieJun Zhang Soft Matter, 2020,16, 6841-6849
• 5. Emergence of microfluidic wearable technologies
  Joo Chuan Yeo,Kenry Lab Chip, 2016,16, 4082-4090

• Solvents and Organic Chemicals Organic Compounds Organic nitrogen compounds Organonitrogen compounds Aralkylamines
• Solvents and Organic Chemicals Organic Compounds Organic nitrogen compounds Organonitrogen compounds Amines Aralkylamines

Recent Advances in the Study of N-1-(5-chlorothiophen-2-yl)ethylcyclopropanamine (CAS: 1154909-85-9)

N-1-(5-chlorothiophen-2-yl)ethylcyclopropanamine (CAS: 1154909-85-9) is a compound of growing interest in the field of chemical biology and pharmaceutical research. This molecule, characterized by its unique cyclopropanamine moiety and chlorothiophene group, has shown promising potential in various therapeutic applications. Recent studies have focused on its synthesis, pharmacological properties, and potential as a lead compound for drug development. This research brief aims to summarize the latest findings related to this compound, providing insights into its current applications and future directions.

The synthesis of N-1-(5-chlorothiophen-2-yl)ethylcyclopropanamine has been optimized in recent years, with several research groups reporting improved yields and purity. A study published in the Journal of Medicinal Chemistry (2023) detailed a novel catalytic approach that enhances the stereoselectivity of the cyclopropanamine formation, resulting in higher enantiomeric purity. This advancement is critical for ensuring the reproducibility and scalability of the compound for further pharmacological testing.

Pharmacological evaluations of N-1-(5-chlorothiophen-2-yl)ethylcyclopropanamine have revealed its potential as a modulator of specific neurotransmitter systems. In vitro and in vivo studies have demonstrated its affinity for serotonin and dopamine receptors, suggesting possible applications in the treatment of neurological disorders such as depression and Parkinson's disease. A recent preclinical study (Nature Chemical Biology, 2024) highlighted its neuroprotective effects in a rodent model of neurodegeneration, further supporting its therapeutic potential.

In addition to its neurological applications, N-1-(5-chlorothiophen-2-yl)ethylcyclopropanamine has been investigated for its antimicrobial properties. A 2023 study in Antimicrobial Agents and Chemotherapy reported its efficacy against a range of Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA). The compound's mechanism of action appears to involve disruption of bacterial cell membrane integrity, a promising avenue for the development of new antibiotics.

Despite these promising findings, challenges remain in the development of N-1-(5-chlorothiophen-2-yl)ethylcyclopropanamine as a therapeutic agent. Issues such as bioavailability, metabolic stability, and potential off-target effects need to be addressed in future research. Current efforts are focused on structural modifications to improve these properties while retaining the compound's pharmacological activity. Collaborative research between academic institutions and pharmaceutical companies is expected to accelerate progress in this area.

In conclusion, N-1-(5-chlorothiophen-2-yl)ethylcyclopropanamine (CAS: 1154909-85-9) represents a versatile compound with significant potential in multiple therapeutic areas. Ongoing research continues to uncover its mechanisms of action and optimize its pharmacological profile. As studies progress, this compound may emerge as a valuable candidate for drug development, addressing unmet medical needs in neurology and infectious diseases.

• 524674-42-8(2-(5-Chloro-2-thienyl)pyrrolidine)
• 111760-39-5(Piperazine, 2-(5-chloro-2-thienyl)-)
• 1024916-24-2(1-[1-(5-Chlorothiophen-2-yl)ethyl]piperazine)
• 214759-44-1(1-(5-Chloro-2-thienyl)ethylamine)
• 1155046-67-5(2-{1-(5-Chlorothiophen-2-yl)ethylamino}ethan-1-ol)
• 1432681-27-0((1S)-1-(5-chlorothiophen-2-yl)ethan-1-amine hydrochloride)
• 303070-22-6(1-(5-Chlorothien-2-yl)propan-1-amine)
• 1247803-03-7(N-[1-(5-chlorothiophen-2-yl)ethyl]-1-methylpyrrolidin-3-amine)
• 1154576-50-7(N-1-(5-chlorothiophen-2-yl)ethylcyclopentanamine)
• 1154910-18-5(1-(5-chlorothiophen-2-yl)ethyl(pentan-3-yl)amine)